Health · Pharma & Biotech · 5 hrs ago
FDA approves Regeneron’s RNAi drug for myasthenia gravis
The FDA approved Regeneron’s Livsayis on Nov.
18 for adults with a common form of generalized myasthenia gravis.
The autoimmune disease can cause debilitating muscle weakness.
Livsayis uses RNA interference to reduce production of C5, a protein involved in the immune response behind the condition.
The drug was discovered by Alnylam and licensed to Regeneron in 2019; it is the company’s first marketed RNAi medicine.
It is also the first RNAi drug approved for an autoimmune condition, showing how this type of treatment may be used beyond its earlier applications.
Livsayis is injected under the skin four times a year and will compete with established treatments from Argenx and AstraZeneca.
Its launch may be gradual as doctors weigh its use and side effects, though its less frequent dosing could help it gain patients over time.
The U.S. Food and Drug Administration approved Regeneron’s Livsayis for adults with generalized myasthenia gravis who have AChR antibodies.
The drug is an RNA interference therapy that reduces production of C5, a protein involved in the immune response.
Livsayis was discovered by Alnylam Pharmaceuticals and licensed to Regeneron in 2019.
It is the first RNAi medicine approved for an autoimmune condition and will compete with established treatments from Argenx and AstraZeneca.
The drug is given by subcutaneous injection four times a year, and its annual list price is $410,000.
- Who
- Regeneron Pharmaceuticals, in collaboration with Alnylam Pharmaceuticals, developed Livsayis.
- What
- The FDA approved Livsayis, an RNA interference therapy, to treat generalized myasthenia gravis in adults with AChR antibodies.
- When
- The FDA approved it on November 18, 2026.
- Where
- United States.
- Why
- It is intended to treat generalized myasthenia gravis by reducing production of C5, a protein implicated in the immune response driving the condition.
RBC Capital Markets analyst Brian Abrahams
TD Cowen analyst Tyler Van Buren
Launch prospects
RBC Capital Markets analyst Brian Abrahams
Abrahams said uptake would likely be measured at first because the drug faces well-entrenched products and physicians want more information.
TD Cowen analyst Tyler Van Buren
Van Buren said the drug’s efficacy and dosing advantage should drive uptake, particularly among patients switching therapies.
Alnylam licensed the drug to Regeneron as part of an RNAi-focused partnership.
The FDA approved Livsayis for generalized myasthenia gravis.
- Brand name
- Livsayis
- Generic name
- cemdisiran
- FDA approval
- Nov. 18, 2026
- Eligible patients
- Adults with AChR antibody-positive generalized myasthenia gravis
- Dosing
- Subcutaneous injection four times a year
- Annual list price
- $410,000
2 sources
What people are saying
Adoption is likely to be “measured at first,
The market is expanding